European Pharmaceutical Review

NOVEMBER 16, 2023

In the past couple of months, BeiGene has experienced regulatory progress for two of its oncology assets in clinical development. According to Data Bridge Market Research, the haematology /oncology market will value $14.83 According to Data Bridge Market Research, the haematology /oncology market will value $14.83

Medicine 52

Medicine Manufacturing Medical Patients 52

European Pharmaceutical Review

NOVEMBER 7, 2023

Positive results for a combination treatment using the first Fc-silent investigational monoclonal antibody in pivotal clinical trials that is designed to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), have been announced. The treatment is being evaluated in patients with upper GI adenocarcinomas.

Safety 97

Safety Patients Physicians Medical 97

Impetus Digital

SEPTEMBER 21, 2022

Register for Impetus’ upcoming live webinar on September 28, 2 – 3 PM ET: A Fireside Chat with Fireside Chat with Dr. Luca Dezzani, VP, US Oncology Medical Affairs at Johnson & Johnson. Luca is now the Vice President of US Oncology Medical Affairs at Johnson & Johnson. About the webinar. About Impetus Digital.

Medical 52

Medical Education Professional Services Physicians 52

European Pharmaceutical Review

JUNE 27, 2023

In April 2023, MaaT Pharma announced that the FDA cleared the Investigational New Drug (IND) application to initiate in the US Phase III pivotal clinical trial evaluating MaaT013 for the treatment of acute graft vs host disease. What are the most promising microbiome therapeutics in clinical development?

Food and Drug Administration 101

Food and Drug Administration Manufacturing Medicine Pharma 101

Pharmacy Times

DECEMBER 16, 2022

Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.

49

49

Pharmaceutical Technology

MAY 30, 2023

Genmab AS’s epcoritamab presents as the top European drug launch and only oncological therapy. Moreover, the top three drug launches are set for first release within this region, further underscoring the prominent role of the US market and its profound influence on the pharmaceutical sector. Similarly, Almirall S.A.,

Sales 105

Sales Marketing Prescription Pharma 105

European Pharmaceutical Review

FEBRUARY 6, 2023

PKC theta plays a critical role in controlling T cell function and is a key driver of several highly prevalent autoimmune diseases. ” Clinical success begins early for small molecule drugs… The need for sustained, high levels of target inhibition was required to drive efficacy.

Sales 89

Sales Pharmaceutical 89

European Pharmaceutical Review

APRIL 12, 2023

In November 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) Innovation Passport was awarded to Boehringer Ingelheim’s investigational BI 907828 in de-differentiated liposarcoma (DDLPS), a rare and aggressive oncology indication for which there has been no new first-line treatment in over forty years.

Medicine 88

Medicine Patients Medical Recruitment 88

European Pharmaceutical Review

JANUARY 9, 2024

TALZENNA the first and only PARP inhibitor licensed in the EU for use with XTANDI for patients with mCRPC, with or without gene mutations” The treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in individuals where chemotherapy is not clinically indicated.

Food and Drug Administration 88

Food and Drug Administration Safety Food Patients 88

European Pharmaceutical Review

APRIL 3, 2023

These results have led to a major amendment in a European Phase III paediatric clinical trial. The oncology treatment showed clinical activity across patients of all ages with the three neuroblastoma-specific hotspot ALK mutations. In 2008, the ALK gene was found to hold a key role in the disease.

Food and Drug Administration 80

Food and Drug Administration Medicine Patients Food 80

Contrarian Sales Techniques

DECEMBER 14, 2022

This year, the sector suffered from various clinical setbacks. Anderson's departure means that Schinecker will take on the role of acting CEO until a replacement is found. In 2019, the company suffered from various clinical setbacks. He returned to his role as the CEO of the company in 2016.

Sales 52

Sales Pharmaceutical Marketing Patients 52

European Pharmaceutical Review

DECEMBER 30, 2023

Oncology continued to dominate the dealmaking in terms of therapeutic area, most notably antibody-drug conjugates (ADCs), which were the key asset in three major deals,” he adds. Strategic partnerships and alliances will continue to play critical roles in early-stage R&D.” What modalities will dominate biopharma dealmaking in 2024?

Biopharma 104

Biopharma Marketing Prospecting Pharmaceutical 104

pharmaphorum

OCTOBER 17, 2022

Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed. Marie-Louise Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development.

Recruitment 97

Recruitment Patients Leads Medicine 97

PM360

DECEMBER 20, 2023

The agreement has a pre-money enterprise value of $500 million and the transaction includes an earnout of up to $300 million tied to various clinical and priced-based milestones. of them are clinically failing first-line ART, 7.6% What role, if any, do your investors play within your company outside of providing funds?

Management 109

Management Marketing Healthcare Healthcare 109

PM360

OCTOBER 26, 2023

As Executive Director Value, Access, and Reimbursement, Cappellino is working cross-functionally, harnessing Klick’s industry-leading clinical, creative, and analytics, to demonstrate the benefits and optimal places in treatment for therapies.

Marketing 52

Marketing Healthcare Healthcare Consulting 52

PM360

MAY 25, 2023

When it comes to decentralized clinical trials (DCTs), arguably the most transformative innovation clinical research has seen in decades, the same is true. Excess documentation and complex mappings can hamper rapid adoption of a better clinical trial model. This is a global revolution, too.

FDA 104

FDA Food and Drug Administration Safety Medicine 104

European Pharmaceutical Review

NOVEMBER 4, 2022

Despite advances with targeted and immuno-oncology therapies, chemotherapies remain a cornerstone of cancer treatment for many tumour types – a reflection of their significant anti?tumour The importance of taxanes in oncology. Taxanes have played an important role in anticancer treatment for several decades. tumour effects.

Food and Drug Administration 86

Food and Drug Administration FDA Pharmaceutical Patients 86

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The post Lantheus on POINT in radio-oncology with $2bn licensing deal appeared first on.

Biopharma 52

Biopharma FDA Pharma Sales 52

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is formulated as tablets for oral route of administration.

Food and Drug Administration 40

Food and Drug Administration Pharmaceutical Food Manufacturing 40

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is formulated as tablets for oral route of administration.

Food and Drug Administration 40

Food and Drug Administration Pharmaceutical Food Manufacturing 40

pharmaphorum

MAY 27, 2022

With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized.

Engineering 52

Engineering Manufacturing Patients 52

pharmaphorum

JANUARY 27, 2023

The emergence of COVID-19 resulted in staffing challenges that have continued to have a sustained, negative impact on clinical trial workflows. The impact of burnout on clinical trials Each staff member involved in a clinical trial is essential to its success.

Physicians 98

Physicians Healthcare Healthcare Patients 98

Pharmaceutical Technology

OCTOBER 7, 2022

“We believe that compelling genetic and experimental evidence of the role for Fzd4-specific Wnt signalling in retinal vascular function points to the potential clinical impact of our approach.”.

Sales 59

Sales Pharmaceutical 59

pharmaphorum

JANUARY 17, 2023

and a clinical group in the UK to test an artificial intelligence-powered technology to help radiologists detecting lung cancer in chest X-rays. The study will look at CT scans and clinical data from 200 patients with confirmed lung cancer who are on systematic therapy, and compare automated assessment using e-ACT to radiologist review.

Patients 92

Patients Government Pharma Training 92

Clarivate

SEPTEMBER 26, 2023

One of the critical factors determining the success of a clinical trial is the selection of appropriate clinical sites that have evidenced access to specific patient populations. Real World Data In recent years, the use of real world data (RWD) has emerged as a powerful tool for enhancing clinical site selection.

Food and Drug Administration 59

Food and Drug Administration Electronics Patients Healthcare 59

Pharmaceutical Technology

JANUARY 2, 2023

Lifirafenib maleate is under clinical development by BeiGene and currently in the Phase II in clinical pathway. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. It targets both epidermal growth factor receptor (EGFR) and B-RAF kinase.

Specialization 40

Specialization Pharmaceutical Medicine Patients 40

European Pharmaceutical Review

OCTOBER 28, 2022

OTX-2002 targets c-Myc (MYC), a key oncogene and master transcription factor that regulates cell proliferation, differentiation and apoptosis and plays a major role in over half of all human cancers. Biotech firm Omega Therapeutics, Inc.

Engineering 104

Engineering Patients Medicine Safety 104

pharmaphorum

NOVEMBER 3, 2022

Its pipeline would be headed by ALKS 2680, an orexin 2 receptor agonist for the treatment of narcolepsy that is building towards the start of clinical testing next year, plus HDAC inhibitors for neurological and neuropsychiatric disorders in preclinical development. Price reforms affecting R&D choices.

Engineering 52

Engineering Pharma Management Leads 52

Pharmaceutical Technology

MARCH 4, 2023

XNW-4107 is under clinical development by Evopoint Bioscience and currently in Phase III for Ventilator Associated Pneumonia (VAP). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company is headquartered in Suzhou, Jiangsu, China.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company operates manufacturing plants in Frosinone, Italy; Camacari Brazil; and Malta.

Manufacturing 40

Manufacturing Pharmaceutical Medicine Marketing 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Manufacturing 40

Manufacturing Pharmaceutical Medicine Marketing 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company operates manufacturing plants in Frosinone, Italy; Camacari Brazil; and Malta.

Manufacturing 40

Manufacturing Pharmaceutical Medicine Marketing 40

European Pharmaceutical Review

AUGUST 24, 2022

In total, there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development. 2 The role of the antibody is to deliver the payload to a specific site such as a cancer cell. An ADC combines the specificity of an antibody and the potent power of an anti?cancer

Engineering 87

Engineering Side effects Marketing Patients 87

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Taken together, the results show that TRODELVY elicits clinically meaningful activity in heavily pretreated HR+ patients regardless of HER2 IHC (ImmunoHistoChemistry) test status.

Marketing 52

Marketing Safety Patients Competition 52

Pharma Leaders

NOVEMBER 21, 2022

Nurse practitioners (NPs) and physician associates (PAs) take an active role in breast cancer treatment for their patients, including detecting early signs of the disease, helping manage prescription side effects and identifying appropriate specialists for patient care. NPs and PAs are clinical in nature but holistic in their approach.

Marketing 52

Marketing Pharma Leads Education 52

European Pharmaceutical Review

NOVEMBER 17, 2022

is found in normal gastric cells and plays a major role in epithelial and endothelial tight junctions controlling the flow of molecules between cells. In pre-clinical studies, this binding interaction caused cancer cell death by activating antibody-dependent cellular toxicity and complement-dependent cytotoxicity immune system pathways. “I

Safety 80

Safety Patients Pharma Pharmaceutical 80

European Pharmaceutical Review

AUGUST 17, 2022

A significant number of drugs fail to reach late-stage clinical trials owing to complications associated with formulation development. With regard to therapeutic area, the oncology segment is likely to witness the fastest CAGR of 8.4 For instance, in 2020, Merck’s R&D cost was approximately $2.5

Marketing 77

Marketing Pharmaceutical Manufacturing Pharma 77